Table 2.
Disease and demographic characteristics of study cohort (BA21, max n = 75)
| Control | PDD | DLB | AD | p-value | |
|---|---|---|---|---|---|
| Maximum n | 18 | 22 | 21 | 14 | |
| Age at death, y | 82.8 (1.2) | 82.4 (1.0) | 83.1 (1.6) | 85.6 (1.5) | 0.41 |
| Female, % | 9 (50.0) | 11 (50.0) | 11 (52.4) | 8 (57.1) | 0.98 |
| Post-mortem intervala, h | 41.5 (5.7) | 37.3 (3.6) | 44.6 (6.2) | 39.0 (6.5) | 0.78 |
| Tissue pH | 6.4 (0.1) | 6.5 (0.1) | 6.2 (0.1) | 6.4 (0.1) | 0.11 |
| MMSE decline per yearb | NA | 2.3 (0.3) | 3.0 (0.5) | 4.0 (1.2) | 0.30 |
| Predeath MMSEc | NA | 10.9 (8.2) | 12.2 (5.1) | 8.4 (7.9) | 0.52 |
| Duration of dementiad, y | NA | 3.7 (0.6) | 6.4 (0.9)† | 9.7 (0.8)† | < 0.001 |
| Duration of parkinsonisme, y | NA | 12.9 (1.3) | 2.9 (0.7) | NA | < 0.001 |
| Braak stagef, n | |||||
| 0–II | 13 | 15 | 4 | 0 | NA |
| III–IV | 0 | 6 | 8 | 2 | NA |
| V–VI | 0 | 1 | 9 | 11 | NA |
| NP scoreg | 0.45 (0.2) | 0.63 (0.1) | 2.10 (0.2)*† | 2.92 (0.1)*† | < 0.001 |
| NFT scoreh | 0.09 (0.1) | 0.37 (0.1) | 1.40 (0.2)*† | 2.83 (0.2)*†‡ | < 0.001 |
| LB scrorei | 0 | 0.89 (0.2)* | 1.75 (0.3)* | 0.25 (0.1)‡ | < 0.001 |
All data expressed in mean (SEM) unless otherwise stated. PDD: Parkinson’s disease dementia; DLB: dementia with Lewy body; AD: Alzheimer’s disease; n: number; y: year; h: hour; MMSE: Mini-Mental State Examination; NA: not applicable
aData on post-mortem interval were not available in 1 PDD case
bData on predeath MMSE were not available in all controls, 2 PDD, 9 DLB and 1 AD cases
cData on MMSE decline per year were not available in all controls, 1 PDD, 6 DLB and 2 AD cases
dData on duration of dementia were not available in all controls, 1 PDD, 6 DLB and 1 AD cases
eData on duration of parkinsonism symptoms were not available in all controls, 1 PDD, 7 DLB and 1 AD cases
fData on Braak stage were not available in 5 controls and 1 AD case
gData on NP score were not available in 2 controls, 3 PDD and 1 AD case
hData on NFT score were not available in 2 controls and 1 AD case
iData on LB score were not available in 7 controls, 1 DLB and 2 AD cases
Dunn–Bonferroni post hoc tests correction was performed following a significant Kruskal–Wallis ANOVA), where significant differences from *Control, †PDD and ‡DLB were indicated accordingly